Marlon Trottmann / Shutterstock.com
Roche subsidiary Spark Therapeutics has settled a lawsuit with rival gene-therapy company Bluebird Bio, which it had accused of infringing its “Spark” trademarks when marketing treatment for sickle-cell disease.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Roche, Bluebird, Spark Therapeutics, US District Court for the District of Delaware, trademarks, sick-cell disease